Heartware International, Inc. (NASDAQ:HTWR) is Expected to Report $-0.55 for Q4

According to analysts, Heartware International, Inc. (NASDAQ:HTWR) is expected to report earnings per share for the current fiscal quarter of $-0.55. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2014-09-30 of $-0.64 for the most recent quarter.

On a consensus basis, Wall Street sell-side analysts have a mean target price of $95.285 for Heartware International, Inc. (NASDAQ:HTWR). This number is based on the mean estimate from the 7 research firms that recently issued reports on the company.The most recent price target update was made on 2015-02-11.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock is ranked 1.88 based on 7 sell-side broker recommendations. Of the 7 analyst estimates, the most bullish sees the stock reaching $110 within the next 12 months while the most bearish analyst sees the stock at $70 within the year. There are currently 1 analysts who have recently rated the stock as a buying opportunity.

In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A . The high end estimate for this time frame is $N/A with the low being $N/A. In looking at the next three to five years, the long term earnings per share estimate growth rate for the company is N/A%, based on N/A analysts providing projections.

Heartware International, Inc. (HeartWare) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. In December 2013, HeartWare International Inc acquired CircuLite, Inc.